HBHelga Bjarnadottir

Helga Bjarnadottir

*This is an algorithmically generated author record based on publicly available information.

Helga Bjarnadottir has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Bjarki Gudmundsson

    Department of Biochemistry and Molecular Biology, University of Iceland, Faculty of Medicine, Reykjavik, Iceland,1 Department of Genetics and Molecular Medicine, Landspitali-University Hospital, Reykjavik, Iceland2

    2 shared publications
  • Bjorn Gudbjornsson

    Centre for Rheumatology Research, Landspitali University Hospital , Reykjavik

    1 shared publication
  • Bjorn Runar Ludviksson

    Department of Immunology, Landspitali-The National University Hospital of Iceland, Hringbraut (Building 14 at Eiriksgata), 101, Reykjavik, Iceland

    1 shared publication
  • G Olafsdottir

    1 shared publication
  • H Tulinius

    1 shared publication
  • Helgi Jonsson

    Department of Orthopaedics, Landspitali - University Hospital, Reykjavik, Iceland

    1 shared publication

Latest Publications

  • Activation of Complement Following Total Hip Replacement

    by Soley Thordardottir, Thora Vikingsdottir, Helga Bjarnadottir, Helgi Jonsson, Bjorn Gudbjornsson

    The aim of this study was to investigate whether complement activation, via the classical and alternative pathways, occurs following a cemented total hip replacement (THR) surgery due to osteoarthritis. Blood samples were collected systematically from 12 patients – six male and six women, with a median age of 75 (range: 59–90 years) – preoperatively, 6 h post‐operatively and on the first, second and third post‐operative day. Total function of classical (CH50) and alternative pathways (AH50) was evaluated, along with the determination of serum concentrations of the complement proteins C3, C4, C3d, the soluble terminal complement complex (sTCC) sC5b‐9, as well as C‐reactive protein (CRP) and albumin. Measurements of CRP and albumin levels elucidated a marked inflammatory response following the operation. The CH50, AH50 and C3 and C4 levels were significantly lower 6 h after the surgery compared with the preoperative levels, but elevated above the preoperative levels during the following 3 days. The complement activation product C3d levels increased continually during the whole observation period, from 13.5 AU/ml (range: 8–19 AU/ml) preoperative to 20 AU/ml (range: 12–34 AU/ml) on the third post‐operative day. Furthermore, we observed an increase in the sC5b‐9 levels between the preoperative and the third post‐operative day. These results demonstrate a significant activation of the complement system following cemented THR. Further studies are needed to elucidate the time frame and the pathogenic role of this observed complement activation.


  • Open Access

    Frequency and distribution of FCN2 and FCN3 functional variants among MBL2 genotypes

    by Helga Bjarnadottir, Margret Arnardottir, Bjorn Runar Ludviksson

    The six types of pattern recognition molecules (PRMs) that initiate complement via the lectin pathway (LP) comprise collectins and ficolins. The importance of having various PRMs to initiate the LP is currently unclear. Mannan-binding lectin (MBL) is a collectin member of the LP PRMs. MBL deficiency is common with mild clinical consequence. Thus, the lack of MBL may be compensated for by the other PRMs. We hypothesized that variants FCN2 + 6424 and FCN3 + 1637delC that cause gene-dose-dependent reduction in ficolin-2 and ficolin-3 levels, respectively, may be rare in MBL-deficient individuals due to the importance of compensation within the LP. The aim of this study was to investigate the distribution and frequency of these variants among MBL2 genotypes in healthy subjects. The allele frequency of FCN2 + 6424 and FCN3 + 1637delC was 0.099 and 0.015, respectively, in the cohort (n = 498). The frequency of FCN2 + 6424 tended to be lower among MBL-deficient subjects (n = 53) than among MBL-sufficient subjects (n = 445) (0.047 versus 0.106, P = 0.057). In addition, individuals who were homozygous for FCN2 + 6424 were sufficient MBL producers. The frequency of FCN3 + 1637delC did not differ between the groups. The frequency of FCN2 + 6424 was similar in FCN3 + 1637delC carriers (n = 15) versus wild type (n = 498). Furthermore, subjects that were heterozygote carriers of both FCN2 + 6424 and FCN3 + 1637delC were sufficient MBL producers. In conclusion, FCN2 + 6424 carriers with MBL deficiency tend to be rare among healthy individuals. MBL-deficient individuals with additional LP PRM defects may be at risk to morbidity.


  • Encapsidation Determinants Located Downstream of the Major Splice Donor in the Maedi-Visna Virus Leader Region

    by Helga Bjarnadottir, Bjarki Gudmundsson, Janus Gudnason, Jon J. Jonsson

    We investigated the role of the 5′-untranslated region between the primer binding site and the gag initiation codon in ovine lentivirus maedi-visna virus (MVV) genomic RNA encapsidation. We identified five computer-predicted stem-loops, three of which were highly conserved in primary sequence and structure. One stable 83-nucleotide (nt) stem-loop (SL4) was not conserved in the primary sequence, but phylogenetic analysis revealed several base pair covariations. The deletion of individual stem-loops did not markedly affect the relative encapsidation efficiency (REE). Only one mutant, carrying a disruption of a 31-nt stem-loop (SL5), had 58% REE in fetal ovine synovial (FOS) cells. A 168-nt deletion (Δ3MSD) downstream of the major splice donor (MSD) which removed three stem-loops, including SL5, resulted in 24% and 20% REE in FOS and 293T cells, respectively. A 100-nt deletion (Δ5MSD) upstream of the MSD resulted in 15-fold lower cellular genomic RNA levels than the wild-type levels in 293T cells. The Δ5MSD mutant and a double mutant (DM) (Δ5MSD and Δ3MSD) did not express detectable levels of virion proteins in 293T cells. In contrast, the region deleted in Δ5MSD was dispensable in FOS cells, and the DM had the same REE as the Δ3MSD virus. Thus, the region upstream of the MSD contains sequences critical for RNA and protein expression in a cell type-specific fashion. Our results indicate that MVV encapsidation determinants are located downstream of the MSD. These results provide comparative insight into lentiviral encapsidation and can be utilized in the design of MVV-based gene transfer vectors.


  • Quantitative assays for maedi-visna virus genetic sequences and mRNA’s based on RT-PCR with real-time FRET measurements

    by Bjarki Gudmundsson, Helga Bjarnadottir, Steinunn Kristjansdottir, Jon J Jonsson


    • 1 May 1997
      • Vol. 60  (5) , 1079-84

    Study of a single BRCA2 mutation with high carrier frequency in a small population.

    by S Thorlacius, S Sigurdsson, H Bjarnadottir, G Olafsdottir, J G Jonasson, L Tryggvadottir, H Tulinius, J E Eyfjörd

    Germ-line changes in the cancer-predisposition gene BRCA2 are found in a small proportion of breast cancers. Mutations in the BRCA2 gene have been studied mainly in families with high risk of breast cancer in females, and male breast cancer also has been associated with BRCA2 mutations. The importance of germ-line BRCA2 mutations in individuals without a family history of breast cancer is unknown. The same BRCA2 mutation has been found in 16/21 Icelandic breast cancer families, indicating a founder effect. We determined the frequency of this mutation, 999del5, in 1,182 Icelanders, comprising 520 randomly selected individuals from the population and a series of 632 female breast cancer patients (61.4% of patients diagnosed during the study period) and all male breast cancer patients diagnosed during the past 40 years. We detected the 999del5 germ-line mutation in 0.6% of the population, in 7.7% of female breast cancer patients, and in 40% of males with breast cancer. The mutation was strongly associated with onset of female breast cancer at age <50 years, but its penetrance and expression are varied. A number of cancers other than breast cancer were found to be increased in relatives of mutation carriers, including those with prostate and pancreatic cancer. Furthermore, germ-line BRCA2 mutation can be present without a strong family history of breast cancer. Comparison of the age at onset for mother/daughter pairs with the 999del5 mutation and breast cancer indicates that age at onset is decreasing in the younger generation. Increase in breast cancer incidence and lower age at onset suggest a possible contributing environmental factor.